High Dose Tamoxifen for Postmenopausal Breast Cancer
Author Information
Author(s): S.M. Watkins
Primary Institution: Department of Medical Oncology, Lister Hospital
Hypothesis
Can high doses of tamoxifen improve outcomes in postmenopausal breast cancer patients who are not responding to standard doses?
Conclusion
Many post-menopausal women with advanced breast cancer benefit from receiving high doses of tamoxifen, resulting in disease stabilization and good quality of life.
Supporting Evidence
- Four patients went into complete remission on high dose tamoxifen.
- Stable disease was observed in over half of the patients.
- Mild side effects were reported, but no patients withdrew from the trial.
Takeaway
This study found that giving higher doses of tamoxifen to women with breast cancer who weren't improving on regular doses helped many feel better and live longer.
Methodology
Patients with advanced breast cancer who progressed on standard doses of tamoxifen were given a higher dose of 90 mg daily, and their responses were assessed over time.
Limitations
The sample size was small, limiting the ability to perform statistical analysis.
Participant Demographics
Participants were postmenopausal women aged 49 to 83, with a mean age of 64.
Want to read the original?
Access the complete publication on the publisher's website